Skip to main content
SpringerLink
Log in

Afatinib

Diarrhoea: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kumari R, et al. Complete response to afatinib in lung adenocarcinoma of epidermal growth factor receptor exon-19 deletion mutation and disease recurrence on drug discontinuation. Journal of Pharmacology and Pharmacotherapeutics 9: 191-194, No. 4, 2018. Available from: URL: http://doi.org/10.4103/jpp.JPP_111_18 - India

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1742, 17 (2019). https://doi.org/10.1007/s40278-019-58475-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-58475-7

Search

Navigation